Trial CTRI/2020/09/027903
Publication Parikh D, Indian Pract (2021) (published paper)
Funding: Private (Intas Pharmaceuticals Ltd., India)
Conflict of interest: Yes
Methods | |
RCT Blinding: Unblinded | |
Location :
Multicenter / India Follow-up duration (days): 28 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
C-IVIG 30 mL IV on day 1 and 2 |
|
Control
Standard care | |
Participants | |
Randomized participants : C-IVIG=30 Standard care=30 | |
Characteristics of participants N= 60 Mean age : NR 44 males Severity : Mild: n=0 / Moderate: n=37 / Severe: n=23 Critical: n=0 Number of vaccinated participants: NR | |
Primary outcome | |
In the register Mean change from Day 1 to Day 8 in clinical outcome of treatment with COVID-19 Hyper-Immuneglobulin (Human) as compared to the control arm as assessed by 8-point ordinal scale | |
In the report mean change from day 1 to day 8 in an 8-point ordinal scale | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Yes |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Some concerns |
General comment |
In addition to the preprint and published articles, the registry (dated Sept 18, 2020) was used for data extraction and analysis. The study achieved the target sample size specified in the trial registry. There is no change from the trial registration in the intervention and control treatments. The primary outcome indicated in registry reflects the primary outcome reported in the paper however, the preprint also reports on incidence of viral conversion (D7) which was not prespecified.
The study was updated on March 17th, 2022 with data extracted from contact with authors. The study was also published in the Indian Practitioner Journal. Data from this is presented. |